These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18813828)

  • 1. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
    Matsumoto K; Nagahara T; Okano J; Murawaki Y
    Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
    Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
    Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth.
    Toyota Y; Iwama H; Kato K; Tani J; Katsura A; Miyata M; Fujiwara S; Fujita K; Sakamoto T; Fujimori T; Okura R; Kobayashi K; Tadokoro T; Mimura S; Nomura T; Miyoshi H; Morishita A; Kamada H; Yoneyama H; Okano K; Suzuki Y; Masaki T
    Int J Oncol; 2015 Oct; 47(4):1293-302. PubMed ID: 26252371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
    Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
    J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.
    Morgan MA; Parsels LA; Parsels JD; Mesiwala AK; Maybaum J; Lawrence TS
    Cancer Res; 2005 Aug; 65(15):6835-42. PubMed ID: 16061666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.
    Kubicka S; Rudolph KL; Tietze MK; Lorenz M; Manns M
    Hepatogastroenterology; 2001; 48(39):783-9. PubMed ID: 11462924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W; Xu B; Li Q; Jiang D; Yan S
    Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition.
    Matsumoto K; Okano J; Nagahara T; Murawaki Y
    Int J Oncol; 2006 Dec; 29(6):1501-8. PubMed ID: 17088989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer.
    Rizell M; Andersson M; Cahlin C; Hafström L; Olausson M; Lindnér P
    Int J Clin Oncol; 2008 Feb; 13(1):66-70. PubMed ID: 18307022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
    Kamada M; Akiyoshi K; Akiyama N; Funamizu N; Watanabe M; Fujioka K; Ikeda K; Manome Y
    Oncol Rep; 2014 Aug; 32(2):829-34. PubMed ID: 24891233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
    Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses.
    Yan T; Desai AB; Jacobberger JW; Sramkoski RM; Loh T; Kinsella TJ
    Mol Cancer Ther; 2004 Sep; 3(9):1147-57. PubMed ID: 15367709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Yokoi K; Fidler IJ
    Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma.
    Hung CS; Lin SF; Liu HH; Kuo LJ; Li LT; Su HY; Liew PL; Lin FY; Wei PL; Liu DZ; Chang YJ
    Ann Surg Oncol; 2012 Aug; 19(8):2744-52. PubMed ID: 22258814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
    Tani S; Murata S; Tamura M; Fukunaga K; Morita M; Hirata Y; Iida H; Kakuno A; Nishigami T; Yamanaka N
    Nihon Shokakibyo Gakkai Zasshi; 2011 Nov; 108(11):1892-901. PubMed ID: 22056711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
    Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
    Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma
    Sungwan P; Kidoikhammouan S; Thonsri U; Saengboonmee C; Wongkham S; Okada S; Seubwai W
    In Vivo; 2024; 38(5):2284-2293. PubMed ID: 39187317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine.
    Lee WP; Tai DI; Tsai SL; Yeh CT; Chao Y; Lee SD; Hung MC
    Cancer Res; 2003 Oct; 63(19):6229-36. PubMed ID: 14559808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.